Analytical Data
-
基因名
LAMP1/CD107a
- Application
-
别名
CD107-A; CD107a; LAMPA; LGP120; Lysosome-associated membrane protein 1; CD107 antigen-like family member A
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P11279
-
表达区间
Ala49~Ser297
-
分子量
57kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LAMP1, also known as CD107a, is a significant lysosomal membrane protein that plays a crucial role in various cellular processes, including autophagy, immune response, and cellular signaling. Research on LAMP1/CD107a has gained momentum due to its implications in the functioning of immune cells, particularly in the context of cytotoxic T lymphocyte (CTL) activity. As a marker for degranulation in CTLs, the expression of LAMP1/CD107a on the cell surface provides insights into the effectiveness of immune responses against tumors and viral infections. Additionally, increased interest in understanding the molecular mechanisms regulating LAMP1/CD107a has led to its potential as a therapeutic target in immunotherapy strategies. By studying the recombinant protein form of LAMP1/CD107a, researchers aim to elucidate its structural and functional aspects, providing a deeper understanding of its involvement in immune modulation. This research could pave the way for novel interventions in cancer therapy and autoimmune diseases, highlighting the relevance of LAMP1/CD107a in enhancing our knowledge of immune system dynamics and developing targeted treatments.
